Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2010

View Archived Issues

Indian scientists claim new inhibitors of TNF-alpha production

Cornerstone Pharma adds new site for phase I/II CPI-613 trials in cancer

Southern Research Institute discloses novel antiviral agents

MannKind discloses new agents for pulmonary drug delivery

Mallinckrodt discovers new diagnostics for renal disorders

Novavax's influenza VLP vaccine triggers cytotoxic T-cell proliferation and IFN-gamma secretion

Clinical data presented on abciximab vs. eptifibatide in PCI

BPR-0912 exhibits antiobesity effects in vivo

Lundbeck identifies highly selective M1 receptor agonist

Lpath provides update on four drug development programs

Galapagos acquires full rights to GLPG-0634 for arthritis

FDA grants fast track status to ACE-031 in Duchenne's muscular dystrophy

Agennix presents update on talactoferrin in cancer and severe sepsis

GlaxoSmithKline presents new antimycobacterial agents

Elder Pharmaceuticals discovers new glucose-lowering agents

Cell Therapeutics reports on second quarter 2010

Italian scientists identify new EGFR inhibitors

Clavis advances phase II gemcitabine elaidate trial in pancreatic cancer

GenVec and Novartis expand collaboration on hearing loss and balance disorders

Impax Laboratories and Perrigo collaborate on topical drug products

FDA to complete review of lorcaserin NDA in October

Glycotope begins phase I trial of GT-MAb 5.2-GEX in cancer

FDA does not grant orphan drug status to Levulan PDT for SCC prevention

FDA approves update of Isentress label with 96-week data of trials in HIV-1 infection

Sunesis partners for phase III VALOR trial of vosaroxin in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...